G2-S16 sulfonate dendrimer as new therapy for treatment failure in HIV-1 entry inhibitors
| Autor: | María Ángeles Muñoz-Fernández, Chueca Natalia, Ignacio Rodriguez-Izquierdo, Federico García |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Dendrimers
Anti-HIV Agents Biomedical Engineering Human immunodeficiency virus (HIV) Medicine (miscellaneous) Bioengineering 02 engineering and technology HIV Envelope Protein gp120 Development medicine.disease_cause Treatment failure Cell Line 03 medical and health sciences chemistry.chemical_compound Dendrimer Drug Resistance Viral medicine Humans General Materials Science Treatment Failure 030304 developmental biology 0303 health sciences Mutation Chemistry Silanes Virus Internalization 021001 nanoscience & nanotechnology Resistance mutation Virology Sulfonate HIV-1 0210 nano-technology After treatment |
| Zdroj: | Nanomedicine. 14:1095-1107 |
| ISSN: | 1748-6963 1743-5889 |
| DOI: | 10.2217/nnm-2018-0364 |
| Popis: | Aim: Polyanionic carbosilane dendrimers have been shown to be safe and block human immunodeficiency virus type 1 (HIV-1) infection in a multifunctional manner. The aim of this study is to evaluate the appearance of HIV-1 resistance mutations after treatment with polyanionic carbosilane dendrimers. Materials & methods: A resistance mutation assay was performed on MT2 cells, viral quantity was measured by ELISA HIVp24gag and titration was carried out on TZM.bl. Next generation sequencing for HIV-1 Env was performed on G1-S4 or G2-S16 dendrimers supernatants. Results: Data showed the appearance of mutation resistance to G1-S4 treatment, inducing three significant mutations. G2-S16 did not generate any mutations and, furthermore, inhibited G1-S4-resistant viruses. Conclusion: G1-S4 treatment generates significant mutations in HIV-1NL4.3. G2-S16 does not generate resistance-associated mutation, suggesting that G2-S16 is safe as a HIV-entry inhibitor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|